Eleven Biotherapeutics

Press Releases
 
Press Releases
Date Title and Summary View
September 20, 2013 Eleven Biotherapeutics Presents Positive Clinical Data on EBI-005, a Targeted Protein Therapeutic for Highly Selective Topical Blockade of IL-1 in Patients with Dry Eye Disease ...
September 5, 2013 Eleven Biotherapeutics to Present at the Stifel Nicolaus 2013 Healthcare Conference ...
June 28, 2013 Eleven Biotherapeutics Announces Positive Topline Data on EBI-005, a Novel Topical IL-1 Inhibitor Protein Therapeutic, in Patients with Dry Eye Disease ...
June 28, 2013 Eleven Biotherapeutics Appoints Industry Veteran Karen L. Tubridy as Chief Development Officer ...
May 28, 2013 Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease ...
May 8, 2013 Eleven Biotherapeutics Presents Data on EBI-005, a Novel IL-1 Inhibitor Protein Therapeutic for Topical Treatment of Dry Eye Disease ...
April 24, 2013 Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting ...
February 19, 2013 Eleven Biotherapeutics Publishes Data on EBI-005, a Novel IL-1 Inhibitor Protein for Topical Treatment of Dry Eye Disease ...
December 19, 2012 Eleven Biotherapeutics Initiates Phase 1b Clinical Study of EBI-005, a Novel, Topically Delivered IL-1 Inhibitor Protein for the Treatment of Dry Eye Disease ...
May 8, 2012 Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing ...
FirstPrevious ...
9
NextLast
Add to Briefcase = add release to Briefcase
NASDAQ: EBIO
Price:
1.45
Change:
- 0.02
Day High:
1.49
Day Low:
1.45
Volume:
10,708
9:56 AM ET on June 22, 2017
Delayed at least 20 minutes.